3.2. Participants and Procedure
The participants were recruited from private practices in Isfahan and Tehran cities, Iran, and outpatient psychiatric wards of clinics affiliated with the University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran, from November 12, 2021, to February 9, 2023.
Patients who met the inclusion criteria were invited to participate in the study. The inclusion criteria included (a) receiving an OCD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), (b) being categorized as contamination/cleaning or danger/checking OCD subtype, (c) having more than 18 years old, (d) being drug-naive, and (e) providing written informed consent.
The Persian version of the Structural Clinical Interview for DSM-5-Research Version (SCID-5-RV) was used for OCD diagnosis. Also, the OCD subtype was evaluated by SCID-5-RV; then, blinded psychologists used The Yale-Brown Obsessive-Compulsive Scale (YBOCS) to confirm this categorizing.
Participants who met the inclusion criteria based on their OCD subtype were placed in danger/checking and contamination/cleaning subtypes, so randomization was not applicable in this stage.
Analysis using G*Power software showed that a sample size of 120 participants would be needed to obtain a statistical power of 95% (α = 0.05), assuming a moderate effect size (0.25). A total sample of 140 participants was recruited to account for potential attrition.
Both groups were evaluated before the intervention. The pre-test evaluation included psychiatric symptoms (using SCID-5-RV), the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) severity section, the demographic characteristics questionnaire, and the clinical variables checklist. We used SCID-5-RV and Y-BOCS for network estimation and determining treatment response (in post-test), respectively.
After the pre-test, patients received the intervention under the supervision of psychiatrists or neurologists blinded to the present research aims. The choice between fluoxetine or fluvoxamine was left to the psychiatrist/neurologist based on the patient's history and other considerations.
The exclusion criteria included: (1) having a current disease with possible interference with treatment procedure, (2) getting pregnant during research, (3) experiencing psychotic disorder/episode, (4) not willing to continue research participation, (5) receiving any parallel psychotherapy during the trial, and (6) experiencing an unexpected event affecting the life process (such as severe illness, death of the family member, or divorce).
One of the most accepted treatment-resistance criteria for OCD definitions is "the presence of a score higher than 16 in the Y-BOCS after at least 12 weeks of an adequate dose of SRIs" (
20,
21). So, after 12 weeks of treatment, we categorized patients into responding and resistant according to the Y-BOCS scores. After this categorizing, we had four groups:
(A) Treatment responders with danger/checking subtype
(B) Treatment responders with contamination/cleaning subtype
(C) Treatment-resistant with danger/checking subtype
(D) Treatment-resistant with contamination/cleaning subtype
So, we used a network perspective to determine differences among these groups. Comprehensive details about the analytic plan regarding these groups are provided in the "statistical analysis" subsection.
Regarding ethical considerations, an individual session (by the first author of the current study) was held for each eligible patient willing to participate in the research. The patients were informed that participation in the survey was voluntary and they could leave the study anytime. Medicines had been approved by the Ministry of Health of Iran. All patient information was collected confidentially and was not shared with third parties. Unwillingness to continue participating in the research had no effect on the treatment process of patients and their health insurance. Finally, the participants could contact the researchers anytime and raise their questions and concerns.
3.6. Statistical Analysis
Data management, descriptive analyses, and network estimation were executed using R-Studio (Desktop Version 4.2.1). Data analysis was done in four steps, as follows:
3.6.1. Step 1: Descriptive Statistics
Data were summarized as numbers (percentages) and mean (standard deviation) for categorical and continuous variables. Independent-sample t-test was used to compare the means between OCD subtypes in continuous variables (e.g., age and age of onset). Also, the comparison between categorical variables (e.g., gender) was made by χ2 test.
3.6.2. Step 2: Comparison of OCD subtypes in Baseline
A network comparison test (NCT) package was utilized to determine whether the networks for contamination/cleaning and danger/checking samples significantly differed in the baseline. The NCT calculates both network invariance (i.e., significant differences in the structure of the networks) and global strength invariance (i.e., significant differences in the global strength [sum of the strength of all of the edges] of the networks). Finally, the results of this comparison indicated whether OCD subtypes should be evaluated separately or combined.
3.6.3. Step 3: Network Estimation of Contamination/Cleaning Subtypes
First, the patients were categorized as treatment-resistant or responders according to the Y-BOCS scores at post-test (for more details about this categorizing, see the "participants and procedure" section). Second, a partial correlation was estimated separately for treatment-resistant and responder groups at baseline (The qgraph package with “qgraph" and “EBICglasso" functions visualized and calculated partial correlation networks).
An undirected Gaussian network's structure was learned by the graphical least absolute shrinkage and selection operator (LASSO) algorithm. By reducing less significant edge weights in the network to 0, LASSO uses L1 regularization to produce a sparse network (
23). As the default for EBICglasso, we utilized an extended bayesian information criterion (EBIC) hyperparameter of gamma = 0.5, which errs on the side of excluding spurious edges (
24).
Third, centrality measures were estimated by betweenness, strength, and closeness of nodes (or psychiatric symptoms) at baseline. Then, the edge weights were measured for accuracy by obtaining 95% confidence intervals (CIs) using the “bootnet" R package; narrower CIs indicate greater accuracy. The centrality indices were also tested for stability using a case-dropping bootstrapping procedure to assess their stability. With the R-package "bootnet" (
25), we calculated the correlation stability coefficient by comparing indices sampled from networks with progressively fewer cases and indices tested from networks sampled from progressively smaller networks. To verify whether two edge weights or two node strengths significantly differed, we used 1,000 bootstrapped samples with a P-value of 0.05.
Finally, we evaluated the network's structure to compare baselines and endpoints and determine whether the connectivity of symptoms varied over time. For example, nodes with the highest connectivity levels at baseline could become poorly connected at endpoints, indicating a significant structural change. Additionally, we evaluated the network's global strength by comparing all edges with the baseline and endpoint. Utilizing the R package “network comparison test," we used a two-tailed permutation test with 5,000 iterations for assessing repeated measurements (
26). Consequently, a difference of P < 0.05 demonstrated a significant difference.
3.6.4. Step 4: Network Estimation of Danger/Checking Subtypes
This step was done in the same way as step 3. All stage 3 analyses were also performed for this subtype.